Accuray Stock Price, News & Analysis (NASDAQ:ARAY)

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Accuray Incorporated (NASDAQ:ARAY) announced its earnings results on Thursday, August, 15th. The medical equipment provider reported ($0.02) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.03 by $0.05. The medical equipment provider earned $117.42 million during the quarter, compared to analysts' expectations of $116.09 million. Accuray had a negative net margin of 3.92% and a negative return on equity of 26.69%. During the same quarter in the prior year, the company earned ($0.01) EPS. View Accuray's Earnings History.

Accuray is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Accuray.

Accuray will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Accuray issued an update on its FY 2020 earnings guidance on Thursday, August, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $410-420 million, compared to the consensus revenue estimate of $436.86 million.

3 brokers have issued 1 year price targets for Accuray's stock. Their predictions range from $3.90 to $4.00. On average, they expect Accuray's stock price to reach $3.95 in the next twelve months. This suggests a possible upside of 48.5% from the stock's current price. View Analyst Price Targets for Accuray.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accuray.

News articles about ARAY stock have been trending negative this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Accuray earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Accuray.

Accuray saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 1,920,000 shares, a decline of 21.3% from the August 30th total of 2,440,000 shares. Based on an average daily volume of 588,200 shares, the short-interest ratio is currently 3.3 days. Currently, 2.2% of the company's stock are short sold. View Accuray's Current Options Chain.

Some companies that are related to Accuray include Luminex (LMNX), Tactile Systems Technology (TCMD), Shockwave Medical (SWAV), Cryolife (CRY), Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT), Cerus (CERS), SurModics (SRDX), Axonics Modulation Technologies (AXNX), Antares Pharma (ATRS), AngioDynamics (ANGO), Intersect ENT (XENT), Orthopediatrics (KIDS), OraSure Technologies (OSUR) and MiMedx Group (MDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include NVIDIA (NVDA), Activision Blizzard (ATVI), Intel (INTC), Advanced Micro Devices (AMD), Tesla (TSLA), Exelixis (EXEL), FireEye (FEYE), Netflix (NFLX), AK Steel (AKS) and AVEO Pharmaceuticals (AVEO).

Accuray's stock is owned by a number of of institutional and retail investors. Top institutional investors include Meeder Asset Management Inc. (0.03%). Company insiders that own Accuray stock include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joseph E Whitters, Joshua Levine, Kevin Waters, Patrick Spine and Shigeyuki Hamamatsu. View Institutional Ownership Trends for Accuray.

ARAY stock was bought by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought Accuray stock in the last two years include Joseph E Whitters and Joshua Levine. View Insider Buying and Selling for Accuray.

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARAY stock can currently be purchased for approximately $2.66.

Accuray has a market capitalization of $236.16 million and generates $418.79 million in revenue each year. The medical equipment provider earns $-16,430,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Accuray employs 998 workers across the globe.View Additional Information About Accuray.

The official website for Accuray is http://www.accuray.com/.

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at m[email protected]